Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Shareholder Meeting (November 2025)
19 slides from Cynata Therapeutics's shareholder meeting presentation, Nov 13, 2025
Slide 1: 2025 Annual General Meeting ASX Announcement
ASX ANNOUNCEMENT 13 November 2025 2025 Annual General Meeting Melbourne, Australia; 13 November 2025: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to release a copy of the Chair’s address an
Slide 2: Chair's Address to Shareholders
Chair’s Address to Shareholders 2025 Annual General Meeting It is my pleasure to address you all today at Cynata’s Annual General Meeting. Following my address, I will invite Kilian and his senior management team to provide an update on the Company’s progress and outlook, including the major clinica
Slide 3: MD's Presentation
For personal use only MD’s Presentation Dr Kilian Kelly CEO & MD 1 cynata.com
Slide 4: Important Information
Important Information Summary information looking words such as ‘expect’, ‘anticipate’, ‘likely’, ‘intend’, ‘should’, ‘could’, ‘may’, ‘predict’, ‘plan’, ‘propose’, ‘will’, This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries (CYP, or ‘believe’, ‘forec
Slide 5: Cynata Snapshot
Cynata Snapshot Next-generation Mesenchymal Stromal Cells (MSCs)1 For personal use only Who we are What are MSCs? Industry Barrier Who we are Our Advantage MSCs are powerful Traditional manufacturing Commercialising CymerusTM, a novel Cynata solves the MSC immune-modulating and relies on continuousl
Slide 6: Capital Structure
Capital Structure Financial Information For personal use only Share price (12 November 2025) A$0.25 Shares on issue ~237.5m Strong balance sheet. Positioned for upside. Market capitalisation ~A$59m Cash1 ~ A$4.9m Backed by institutions: Fidelity, BioScience Managers, and Fujifilm among top holders T
Slide 7: Cynata Is At An Inflection Point
Cynata Is At An Tightly focused clinical pipeline Inflection Point Phase 1 Phase 2 Phase 3 Market Size Next Catalyst* For personal use only Ongoing Osteoarthritis Results: US$11.6bn3 Q2 CY 2026 CYP-004 Advancing four clinical programs Acute Graft vs Ongoing to address critical treatment gaps Results
Slide 8: FY 2025 Highlights
For personal use only FY 2025 Highlights 6 cynata.com
Slide 9: FY25 Clinical Program Highlights
FY25 Clinical Program Highlights For personal use only Diabetic Food Ulcers Kidney Transplantation • First patient treated at Leiden University • Phase 1 trial completed – positive safety and Medical Centre (LUMC) during FY25. efficacy outcomes (see next slide). • First cohort (n=3) completed post F
Slide 10: CYP-006TK DFU Phase 1 Trial Results
CYP-006TK | DFU Phase 1 Trial Results Primary Objective Achieved For personal use only CYP-006TK safe and well-tolerated; no withdrawals due to adverse events; no suspected serious adverse reactions Mean change in wound surface area (all wounds) Larger wounds measuring >200mm2 These results are high
Slide 11: FY25 Pre-Clinical Highlights
FY25 Pre-Clinical Highlights For personal use only Expanding the therapeutic potential of CymerusTM Cardiovascular (Heart Disease Model) Cardiovascular Diseases • In an ischaemia-reperfusion model of heart disease, Cymerus MSCs encapsulated in an implantable device* improved cardiac function, reduce
Slide 12: Independent Validation of Superior Properties of Cymerus MSCs
Independent Validation of Superior Properties of Cymerus MSCs For personal use only Peer-reviewed Publication Results Published in Nature’s npj Regenerative Medicine (Feb 2025)1 Direct comparison showed iPSC-derived MSCs outperformed bone marrow and adipose MSCs, with: Greater consistency and potenc
Slide 13: FY25 Regulatory & Corporate Progress
FY25 Regulatory & Corporate Progress For personal use only Strengthening regulatory position and corporate foundations First FDA approval of an MSC-based product (Mesoblast’s Ryoncil®; for paediatric steroid-resistant acute GvHD) is a major positive milestone for the field, which does not impede Cyn
Slide 14: Our Advantage & Outlook
For personal use only Our Advantage & Outlook 12 cynata.com
Slide 15: Our Manufacturing Advantage
Our Manufacturing Advantage For personal use only Conventional MSC Manufacturing CymerusTM Manufacturing • MSCs sourced from donated tissue (e.g. bone marrow); • Single blood donation → converted to induced ongoing supply of new donors required pluripotent stem cells (iPSCs) • Requires cell isolatio
Slide 16: What Our Manufacturing Breakthrough Unlocks
What Our Manufacturing For personal use only Breakthrough Unlocks From scientific first to leadership in MSC medicine. 1. Allows Cynata to undertake clinical trials using a potent, consistent product 2. Eliminates decades-old barrier to scalable MSC commercialisation 3. Only Company that can produce
Slide 17: The Next 6-9 Months Will Define Cynata
The Next 6-9 Months Will Define Cynata Upcoming Landmark Readouts Later stage results could become a strategic trigger For personal use only Market Size Next Catalyst* Licensing / Partnering Phase 3 Results: • Positive Phase 2 & 3 results can trigger regional or indication-specific deals Osteoarthri
Slide 18: The Investment Case: Why Cynata? Why Now?
Service One Service Three For personal use only But I must But I must Solves the MSC First mover with no Lead asset backed explain to you explain to you manufacturing direct peers - only by FDA Orphan Drug The how this bottleneck with single- clinical grade iPSC how this and designation donor scalab
Slide 19: Thank You
For personal use only Thank You. Cynata Therapeutics Limited Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia +61 (03) 7067 6940 investors@cynata.com www.cynata.com
Cynata Therapeutics — Shareholder Meeting (November 2025) on 6ix